HRP20130063T1 - Inhibitori virusa hepatitisa c - Google Patents

Inhibitori virusa hepatitisa c Download PDF

Info

Publication number
HRP20130063T1
HRP20130063T1 HRP20130063AT HRP20130063T HRP20130063T1 HR P20130063 T1 HRP20130063 T1 HR P20130063T1 HR P20130063A T HRP20130063A T HR P20130063AT HR P20130063 T HRP20130063 T HR P20130063T HR P20130063 T1 HRP20130063 T1 HR P20130063T1
Authority
HR
Croatia
Prior art keywords
pyrrolidinyl
methyl
benzimidazol
imidazol
methoxycarbonyl
Prior art date
Application number
HRP20130063AT
Other languages
English (en)
Inventor
Jeffrey Lee Romine
Denis R. St. Laurent
Makonen Belema
Lawrence B. Snyder
Lawrence G. Hamann
John F. Kadow
Jayne Kapur
Andrew C. Good
Omar D. Lopez
Rico Lavoie
John A. Bender
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20130063T1 publication Critical patent/HRP20130063T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (27)

1. Spoj Formule (I) [image] ili njegova farmaceutski prihvatljiva sol, gdje svaki m je nezavisno 0 ili 1; svaki n je nezavisno 0 ili 1; L je veza ili se izabire između [image] i [image] gdje je svaka skupina prikazana s lijevim krajem spojenim za benzimidazol i desnim krajem spojenim s R1; R1 se izabire između [image] svaki R2 je nezavisno izabran između alkila i halogena; svaki R3 je nezavisno izabran između vodika i -C(O)R7; R4 je alkil; R5 i R6 su nezavisno izabrani između vodika, alkila, cijanoalkila, i halogena, ili R5 i R6, zajedno s atomom ugljika s kojim su spojeni, formiraju šesteročlani ili sedmeročlani prsten koji po izboru sadrži jedan heteroatom izabran između dušika i kisika i po izboru sadrži dodatnu dvostruku vezu; i svaki R7 je nezavisno izabran između alkoksi, alkil, arilalkoksi, arilalkil, cikloalkil, (cikloalkil)alkil, heterociklil, heterociklilalkil, (NRcRd)alkenil, i (NRcRd)alkil.
2. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, gdje L je veza.
3. Spoj prema zahtjevu 2, ili njegova farmaceutski prihvatljiva sol, gdje je R1 [image]
4. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, gdje je L [image]
5. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, gdje je L [image]
6. Spoj prema zahtjevu 5, ili njegova farmaceutski prihvatljiva sol, gdje se R1 izabire između [image] i [image]
7. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, gdje je L [image]
8. Spoj prema zahtjevu 7, ili njegova farmaceutski prihvatljiva sol, gdje se L izabire između [image] i [image]
9. Spoj prema zahtjevu 8, ili njegova farmaceutski prihvatljiva sol, gdje je R1 [image]
10. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, gdje je L [image]
11. Spoj prema zahtjevu 10, ili njegova farmaceutski prihvatljiva sol, gdje je R1 [image]
12. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, gdje se L izabire između [image] i [image] gdje je svaka skupina prikazana s lijevim krajem spojenim za benzimidazol i desnim krajem spojenim s R1.
13. Spoj prema zahtjevu 12, ili njegova farmaceutski prihvatljiva sol, gdje je R1 [image]
14. Spoj Formule (II) [image] ili njegova farmaceutski prihvatljiva sol, gdje svaki m je nezavisno 0 ili 1; svaki n je nezavisno 0 ili 1; L je veza ili se izabire između [image] i [image] R1 se izabire između [image] i [image] svaki R2 je nezavisno izabran između alkila i halogena; svaki R3 je nezavisno izabran između vodika i -C(O)R7; R4 je alkil; R5 i R6 su nezavisno vodik ili halogen, ili R5 i R6, zajedno s atomom ugljika s kojim su spojeni, formiraju šesteročlani ili sedmeročlani prsten koji po izboru sadrži jedan heteroatom izabran između dušika i kisika i po izboru sadrži dodatnu dvostruku vezu; i svaki R7 je nezavisno izabran između alkoksi, alkil, arilalkil, cikloalkil, heterociklil, heterociklilalkil, (NRcRd) alkenil, i (NRcRd)alkil.
15. Spoj izabran između metil ((1S)-1-(((2S)-2-(8-(4-(2-((2S)-1-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-pirolidinil)-1Himidazol-4-il)fenil)-1,4,5,6-tetrahidrobenzo[3,4]ciklohepta[1,2-d]imidazol-2-il)-1-pirolidinil)karbonil)-2-metilpropil)karbamat; (1R)-2-((2S)-2-(8-(2-((2S)-1-((2R)-2-(dietilamino)-2-fenilacetil)-2-pirolidinil)-1H-benzimidazol-5-il)-1,4,5,6-tetrahidrobenzo[3,4]ciklohepta[1,2-d]imidazol-2-il)-1-pirolidinil)-N,N-dietil-2-okso-1-feniletanamin; metil ((1S)-1-(((2S)-2-(5-(4-(2-((2S)-1-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-pirolidinil)-1Himidazol-4-il)fenil)-1H-benzimidazol-2-il)-1-pirolidinil)karbonil)-2-metilpropil)karbamat; (1R)-2-((2S)-2-(4-(4-(2-((2S)-1-((2R)-2-(dietilamino)-2-fenilacetil)-2-pirolidinil)-1H-benzimidazol-5-il)fenil)-1H-imidazol-2-il)-1-pirolidinil)-N,N-dietil-2-okso-I-feniletanamin; metil ((1R)-2-((2S)-2-(4-(4-(2-((2S)-1-((2R)-2-((metoksikarbonil)amino)-2-fenilacetil)-2-pirolidinil)-1H-benzimidazol-5-il)fenil)-1H-imidazol-2-il)-1-pirolidinil)-2-okso-1-feniletil)karbamat; metil ((1S)-1-(((2S)-2-(5-(3-(2-((2S)-1-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-pirolidinil)-1Himidazol-4-il)fenil)-1H-benzimidazol-2-il)-1-pirolidinil)karbonil)-2-metilpropil)karbamat; (1R)-2-((2S)-2-(4-(3-(2-((2S)-1-((2R)-2-(dietilamino)-2-fenilacetil)-2-pirolidinil)-1H-benzimidazol-5-il)fenil)-1H-imidazol-2-il)-1-pirolidinil)-N,N-dietil-2-okso-1-feniletanamin; metil ((1R)-2-((2S)-2-(4-(3-(2-((2S)-1-((2R)-2-((metoksikarbonil)amino)-2-fenilacetil)-2-pirolidinil)-1H-benzimidazol-5-il)fenil)-1H-imidazol-2-il)-1-pirolidinil)-2-okso-1-feniletil)karbamat; metil ((1S)-1-(((1R,3S,5R)-3-(8-(2-((1R,3S,5R)-2-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-azabiciklo[3.1.0]hex-3-il)-1H-benzimidazol-5-il)-1,4,5,6-tetrahidrobenzo[3,4]ciklohepta[1,2-d]imidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)karbonil)-2-metilpropil)karbamat; metil ((1S)-1-(((2S)-2-(5-(2-((2S)-1-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-pirolidinil)-4,5-dihidro-3H-nafto[1,2-d]imidazol-7-il)-1H-benzimidazol-2-il)-1-pirolidinil)karbonil)-2-metilpropil)karbamat; metil ((1S)-1-(((2S)-2-(5-(4’-(2-((2S)-1-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-pirolidinil)-1Himidazol-4-il)-4-bifenilil)-1H-benzimidazol-2-il)-1-pirolidinil)karbonil)-2-metilpropil)karbamat; metil ((1S)-1-(((2S)-2-(5-(2-((2S)-1-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-pirolidinil)-3Hnafto[1,2-d]imidazol-7-il)-1H-benzimidazol-2-il)-1-pirolidinil)karbonil)-2-metilpropil)karbamat; (1R)-2-((2R)-2-(7-(2-((2S)-1-((2R)-2-(dietilamino)-2-fenilacetil)-2-pirolidinil)-1H-benzimidazol-5-il)-1Hnafto[1,2-d]imidazol-2-il)-1-pirolidinil)-N,N-dietil-2-okso-1-feniletanamin; metil ((1S)-1-(((2S)-2-(5-(4-(2-((2S)-1-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-pirolidinil)-1Hnafto[1,2-d]imidazol-7-il)fenil)-1H-benzimidazol-2-il)-1-pirolidinil)karbonil)-2-metilpropil)karbamat; metil ((1R)-2-((2S)-2-(7-(4-(2-((2S)-1-((2R)-2-((metoksikarbonil)amino)-2-fenilacetil)-2-pirolidinil)-1H-benzimidazol-5-il)fenil)-1H-nafto[1,2-d]imidazol-2-il)-1-pirolidinil)-2-okso-1-feniletil)karbamat; metil ((1S)-1-(((2S)-2-(5-((4-(2-((2S)-1-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-pirolidinil)-1Himidazol-4-il)fenil)ethynil)-1H-benzimidazol-2-il)-1-pirolidinil)karbonil)-2-metilpropil)karbamat; (1R)-2-((2S)-2-(4-(4-((2-((2S)-1-((2R)-2-(dietilamino)-2-fenilacetil)-2-pirolidinil)-1H-benzimidazol-5-il)etinil)fenil)-1H-imidazol-2-il)-1-pirolidinil)-N,N-dietil-2-okso-1-feniletanamin; metil ((1S)-1-(((2S)-2-(5-((4-(4-etil-2-((2S)-1-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-pirolidinil)-1H-imidazol-5-il)fenil)etinil)-1H-benzimidazol-2-il)-1-pirolidinil)karbonil)-2-metilpropil)karbamat; metil ((1S)-1-(((2S)-2-(4-(cijanometil)-5-(4-((2-((2S)-1-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-pirolidinil)-1H-benzimidazol-5-il)etinil)fenil)-1H-imidazol-2-il)-1-pirolidinil)karbonil)-2-metilpropil)karbamat; metil ((1S)-1-(((1R,3S,5R)-3-(5-((4-(2-((1R,3S,5R)-2-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-azabiciklo[3.1.0]heks-3-il)-1H-imidazol-4-il)fenil)etinil)-1H-benzimidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)karbonil)-2-metilpropil)karbamat; metil ((1S)-1-(((1R,3S,5R)-3-(4-(4-((4-fluoro-2-((1R,3S,5R)-2-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-azabiciklo[3.1.0]heks-3-il)- H-benzimidazol-6-il)etinil)fenil)-1H-imidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)karbonil)-2-metilpropil)karbamat; metil ((1S)-1-(((1R,3S,5R)-3-(4-(2-fluoro-4-((2-((1R,3S,5R)-2-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-azabiciklo[3.1.0]heks-3-il)-1H-benzimidazol-5-il)etinil)fenil)-1H-imidazol-2-il)-2-azabiciklo [3.1.0]heks-2-il)karbonil)-2-metilpropil)karbamat; metil ((1S)-1-(((2S)-2-(5-((2-((2S)-1-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-pirolidinil)-4,5-dihidro-3H-nafto[1,2-d]imidazol-7-il)etinil)-1H-benzimidazol-2-il)-1-pirolidinil)karbonil)-2-metilpropil)karbamat; metil ((1R)-2-((2S)-2-(7-((2-((2S)-1-((2R)-2-((metoksikarbonil)amino)-2-fenilacetil)-2-pirolidinil)-1H-benzimidazol-5-il)etinil)-4,5-dihidro-1H-nafto[1,2-d]imidazol-2-il)-1-pirolidinil)-2-okso-1-feniletil)karbamat; metil ((1S)-1-(((2S)-2-(5-((2-((2S)-1-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-pirolidinil)-3Hnafto[1,2-d]imidazol-7-il)etinil)-1H-benzimidazol-2-il)-1-pirolidinil)karbonil)-2-metilpropil)karbamat; metil ((1R)-2-((2S)-2-(7-((2-((2S)-1-((2R)-2-((metoksikarbonil)amino)-2-fenilacetil)-2-pirolidinil)-1H-benzimidazol-5-il)etinil)- 1H-nafto[ 1,2-d] imidazol-2-il)-1-pirolidinil)-2-okso-1-feniletil)karbamat; metil ((1S)-1-(((2S)-2-(4-fluoro-6-((2-((2S)-1-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-pirolidinil)-4,5-dihidro-1H-nafto[1,2-d]imidazol-7-il)etinil)-1H-benzimidazol-2-il)-1-pirolidinil)karbonil)-2-metilpropil)karbamat; metil ((1S)-1-(((2S)-2-(4-fluoro-6-((2-((2S)-1-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-pirolidinil)-1H-nafto[1,2-d]imidazol-7-il)etinil)-1H-benzimidazol-2-il)-1-pirolidinil)karbonil)-2-metilpropil)karbamat; metil ((1S)-1-(((1R,3S,5R)-3-(5-((2-((1R,3S,5R)-2-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-azabiciklo[3.1.0]heks-3-il)-4,5-dihidro-1 1H-nafto[1,2-d]imidazol-7-il)etinil)-1H-benzimidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)karbonil)-2-metilpropil)karbamat; metil ((1R)-2-((1R,3S,5R)-3-(7-((2-((1R,3S,5R)-2-((2R)-2-((metoksikarbonil)amino)-2-fenilacetil)-2-azabiciklo[3.1.0]heks-3-il)-1H-benzimidazol-5-il)etinil)-4,5-dihidro-1H-nafto[1,2-d]imidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)-2-okso-1-feniletil)karbamat; metil ((1S)-1-(((1R,3S,5R)-3-(5-((2-((1R,3S,5R)-2-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-azabiciklo[3.1.0]heks-3-il)-1H-nafto[1,2-d]imidazol-7-il)etinil)-1H-benzimidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)karbonil)-2-metilpropil)karbamat; metil ((1R)-2-((1R,3S,5R)-3-(7-((2-((1R,3S,5R)-2-((2R)-2-((metoksikarbonil)amino)-2-fenilacetil)-2-azabiciklo[3.1.0]heks-3-il)-1H-benzimidazol-5-il)etinil)-1H-nafto[1,2-d]imidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)-2-okso-1-feniletil)karbamat; metil ((1S)-1-(4,4-difluorocikloheksil)-2-((1R,3S,5R)-3-(7-((2-((1R,3S,5R)-2-((2S)-2-(4,4-difluorocikloheksil)-2-((metoksikarbonil)amino)acetil)-2-azabiciklo[3.1.0]heks-3-il)-1H-benzimidazol-5-il)etinil)-1H-nafto[1,2-d]imidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)-2-oksoetil)karbamat; metil ((1S)-2-((1R,3S,5R)-3-(7-((2-((1R,3S,5R)-2-((2S)-2-((metoksikarbonil)amino)-2-(tetrahidro-2H-piran-4-il)acetil)-2-azabiciklo[3.1.0]heks-3-il)-1H-benzimidazol-5-il)etinil)-1H-nafto[1,2-d]imidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)-2-okso-1-(tetrahidro-2H-piran-4-il)etil)karbamat; metil ((1S)-2-((1R,3S,5R)-3-(7-((2-((1R,3S,5R)-2-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-azabiciklo[3.1.0]heks-3-il)-1H-benzimidazol-5-il)etinil)-1H-nafto[1,2-d]imidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)-2-okso-1-(tetrahidro-2H-piran-4-il)etil)karbamat; metil ((1S)-1-(((1R,3S,5R)-3-(4-fluoro-6-((2-((1R,3S,5R)-2-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-azabiciklo[3.1.0]heks-3-il)-4,5-dihidro-1H-nafto [1,2-d]imidazol-7-il)etinil)-1H-benzimidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)karbonil)-2-metilpropil)karbamat; metil ((1S)-1-(((1R,3S,5R)-3-(4-fluoro-6-((2-((1R,3S,5R)-2-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-azabiciklo[3.1.0]heks-3-il)-1H-nafto[1,2-d]imidazol-7-il)etinil)-1H-benzimidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)karbonil)-2-metilpropil)karbamat; benzil (1R,3S,55R)-3-(7-((2-((1R,3S,5R)-2-(N-(metoksikarbonil)-L-valil)-2-azabiciklo[3.1.0]heks-3-il)-1H-benzimidazol-5-il)etinil)-1H-nafto[1,2-d]imidazol-2-il)-2-azabiciklo[3.1.0]heksane-2-karboksilat; metil ((1S)-1-(((2S)-2-(5-(3-((2-((2S)-1-((2R)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-pirolidinil)-1Hbenzimidazol-5-il)etinil)fenil)-1H-imidazol-4-il)-1-pirolidinil)karbonil)-2-metilpropil)karbamat; (1R)-2-((2S)-2-(5-(3-((2-((2S)-1-((2R)-2-(dietilamino)-2-fenilacetil)-2-pirolidinil)-1H-benzimidazol-5-il)etinil)fenil)-1H-imidazol-4-il)-1-pirolidinil)-N,N-dietil-2-okso- 1-feniletanamin; metil ((1S)-1-(((2S)-2-(5-((4-(4-((2S)-1-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-pirolidinil)-1Himidazol-5-il)fenil)etinil)-1H-benzimidazol-2-il)-1-pirolidinil)karbonil)-2-metilpropil)karbamat; metil ((1S)-1-(((2S,5S)-2-(5-((2-((2S,5S)-1-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-5-metil-2-pirolidinil)-1H-nafto[1,2-d]imidazol-7-il)etinil)-1H-benzimidazol-2-il)-5-metil-1-pirolidinil)karbonil)-2-metilpropil)karbamat; metil ((1S)-2-((2S,5S)-2-(7-((2-((2S,5S)-1-((2S)-2-((metoksikarbonil)amino)-2-(tetrahidro-2H-piran-4-il)acetil)-5-metil-2-pirolidinil)-1H-benzimidazol-5-il)etinil)-1H-nafto[1,2-d]imidazol-2-il)-5-metil-1-pirolidinil)-2-okso-1-(tetrahidro-2H-piran-4-il)etil)karbamat; metil ((1S)-1-(((1R,3S,5R)-3-(7-(2-(2-((1R,3S,5R)-2-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-azabiciklo[3.1.0]heks-3-il)-1H-benzimidazol-5-il)etil)-1H-nafto[1,2-d]imidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)karbonil)-2-metilpropil)karbamat; metil ((1S)-2-((1R,3S,5R)-3-(7-(2-(2-((1R,3S,5R)-2-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-azabiciklo[3.1.0]heks-3-il)-1H-benzimidazol-5-il)etil)-1H-nafto[1,2-d]imidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)-2-okso-1-(tetrahidro-2H-piran-4-il)etil)karbamat; (S)-1-acetil-N-(4-((2-((S)-1-(2-fenilacetil)pirolidin-2-il)-1H-benzo[d]imidazol-6-il)etinil)fenil)pirolidin-2-karboksamid; (S)-1-(2-fenilacetil)-N-(4-((2-((S)-1-(2-fenilacetil)pirolidin-2-il)-1H-benzo[d]imidazol-6-il)etinil)fenil)pirolidin-2-karboksamid; (S)-1-acetil-N-(4-(2-(2-((S)-1-(2-fenilacetil)pirolidin-2-il)-1H-benzo[d]imidazol-6-il)etil)fenil)pirolidin-2-karboksamid; (S)-1-(2-fenilacetil)-N-(4-(2-(2-((S)-1-(2-fenilacetil)pirolidin-2-il)-1H-benzo[d]imidazol-6-il)etil)fenil)pirolidin-2-karboksamid; metil ((1R)-2-((2S)-2-((5-(2-(2-((2S)-1-((2R)-2-((metoksikarbonil)amino)-2-fenilacetil)-2-pirolidinil)-1H-benzimidazol-5-il)-1,3-oxazol-5-il)-2-metilfenil)karbamoil)-1-pirolidinil)-2-okso-1-feniletil)karbamat; metil (R)-2-((S)-2-(S-(2-(2-((S)-1-((R)-2-(dimetilamino)-2-fenilacetil)pirolidin-2-il)-1H-benzo[d]imidazol-5-il)oxazol-5-il)-2-metilfenilkarbamoil)pirolidin-1-il)-2-okso-1-feniletilkarbamat; metil ((1R)-2-((2S)-2-((3-(2-(2-((2S)-1-((2R)-2-((metoksikarbonil)amino)-2-fenilacetil)-2-pirolidinil)-1H-benzimidazol-5-il)-1,3-oksazol-5-il)fenil)karbamoil)-1-pirolidinil)-2-okso-1-feniletil)karbamat; metil ((1R)-2-((1R,3S,5R)-3-(7-((2-((1R,3S,5R)-2-((2R)-2-((metoksikarbonil)amino)-2-fenilacetil)-2-azabiciklo[3.1.0]heks-3-il)-1H-benzimidazol-5-il)etinil)-4,5-dihidro-1H-nafto[1,2-d]imidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)-2-okso-1-feniletil)karbamat; metil ((1S)-1-(((1R,3S,5R)-3-(5-((2-((1R,3S,5R)-2-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-azabiciklo[3.1.0]heks-3-il)-1H-nafto[1,2-d]imidazol-7-il)etinil)-1H-benzimidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)karbonil)-2-metilpropil)karbamat; metil ((1R)-2-((1R,3S,5R)-3-(7-((2-((1R,3S,5R)-2-((2R)-2-((metoksikarbonil)amino)-2-fenilacetil)-2-azabiciklo[3.1.0]heks-3-il)-1H-benzimidazol-5-il)etinil)-1H-nafto[1,2-d]imidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)-2-okso-1-feniletil)karbamat; metil ((1S)-1-(4,4-difluorocikloheksil)-2-((1R,3S,5R)-3-(7-((2-((1R,3S,5R)-2-((2S)-2-(4,4-difluorocikloheksil)-2-((metoksikarbonil)amino)acetil)-2-azabiciklo[3.1.0]heks-3-il)-1H-benzimidazol-5-il)etinil)-1H-nafto[1,2-d]imidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)-2-oksoetil)karbamat; metil ((1S)-2-((1R,3S,5R)-3-(7-((2-((1R,3S,5R)-2-((2S)-2-((metoksikarbonil)amino)-2-(tetrahidro-2H-piran-4-il)acetil)-2-azabiciklo[3.1.0]heks-3-il)-1H-benzimidazol-5-il)etinil)-1H-nafto[1,2-d]imidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)-2-okso-1-(tetrahidro-2H-piran-4-il)etil)karbamat; metil ((1S)-2-((1R,3S,5R)-3-(7-((2-((1R,3S,5R)-2-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-azabiciklo[3.1.0]heks-3-il)-1H-benzimidazol-5-il)etinil)-1H-nafto[1,2-d]imidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)-2-okso-1-(tetrahidro-2H-piran-4-il)etil)karbamat; metil ((1S)-1-(((1R,3S,5R)-3-(4-fluoro-6-((2-((1R,3S,5R)-2-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-azabiciklo[3.1.0]heks-3-il)-4,5-dihidro-1H-nafto [1,2-d]imidazol-7-il)etinil)-1H-benzimidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)karbonil)-2-metilpropil)karbamat; metil ((1S)-1-(((1R,3S,5R)-3-(4-fluoro-6-((2-((1R,3S,5R)-2-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-azabiciklo[3.1.0]heks-3-il)-1H-nafto[1,2-d]imidazol-7-il)etinil)-1H-benzimidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)karbonil)-2-metilpropil)karbamat; benzil (1R,3S,55R)-3-(7-((2-((1R,3S,5R)-2-(N-(metoksikarbonil)-L-valil)-2-azabiciklo[3.1.0]heks-3-il)-1H-benzimidazol-5-il)etinil)-1H-nafto[1,2-d]imidazol-2-il)-2-azabiciklo[3.1.0]heksane-2-karboksilat; metil ((1S)-1-(((2S)-2-(5-(3-((2-((2S)-1-((2R)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-pirolidinil)-1Hbenzimidazol-5-il)etinil)fenil)-1H-imidazol-4-il)-1-pirolidinil)karbonil)-2-metilpropil)karbamat; (1R)-2-((2S)-2-(5-(3-((2-((2S)-1-((2R)-2-(dietilamino)-2-fenilacetil)-2-pirolidinil)-1H-benzimidazol-5-il)etinil)fenil)-1H-imidazol-4-il)-1-pirolidinil)-N,N-dietil-2-okso- 1-feniletanamin; metil ((1S)-1-(((2S)-2-(5-((4-(4-((2S)-1-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-pirolidinil)-1Himidazol-5-il)fenil)etinil)-1H-benzimidazol-2-il)-1-pirolidinil)karbonil)-2-metilpropil)karbamat; metil ((1S)-1-(((2S,5S)-2-(5-((2-((2S,5S)-1-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-5-metil-2-pirolidinil)-1H-nafto[1,2-d]imidazol-7-il)etinil)-1H-benzimidazol-2-il)-5-metil-1-pirolidinil)karbonil)-2-metilpropil)karbamat; metil ((1S)-2-((2S,5S)-2-(7-((2-((2S,5S)-1-((2S)-2-((metoksikarbonil)amino)-2-(tetrahidro-2H-piran-4-il)acetil)-5-metil-2-pirolidinil)-1H-benzimidazol-5-il)etinil)-1H-nafto[1,2-d]imidazol-2-il)-5-metil-1-pirolidinil)-2-okso-1-(tetrahidro-2H-piran-4-il)etil)karbamat; metil ((1S)-1-(((1R,3S,5R)-3-(7-(2-(2-((1R,3S,5R)-2-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-azabiciklo[3.1.0]heks-3-il)-1H-benzimidazol-5-il)etil)-1H-nafto[1,2-d]imidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)karbonil)-2-metilpropil)karbamat; metil ((1S)-2-((1R,3S,5R)-3-(7-(2-(2-((1R,3S,5R)-2-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-azabiciklo[3.1.0]heks-3-il)-1H-benzimidazol-5-il)etil)-1H-nafto[1,2-d]imidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)-2-okso-1-(tetrahidro-2H-piran-4-il)etil)karbamat; (S)-1-acetil-N-(4-((2-((S)-1-(2-fenilacetil)pirolidin-2-il)-1H-benzo[d]imidazol-6-il)etinil)fenil)pirolidin-2-karboksamid; (S)-1-(2-fenilacetil)-N-(4-((2-((S)-1-(2-fenilacetil)pirolidin-2-il)-1H-benzo[d]imidazol-6-il)etinil)fenil)pirolidin-2-karboksamid; (S)-1-acetil-N-(4-(2-(2-((S)-1-(2-fenilacetil)pirolidin-2-il)-1H-benzo[d]imidazol-6-il)etil)fenil)pirolidin-2-karboksamid; (S)-1-(2-fenilacetil)-N-(4-(2-(2-((S)-1-(2-fenilacetil)pirolidin-2-il)-1H-benzo[d]imidazol-6-il)etil)fenil)pirolidin-2-karboksamid; metil ((1R)-2-((2S)-2-((5-(2-(2-((2S)-1-((2R)-2-((metoksikarbonil)amino)-2-fenilacetil)-2-pirolidinil)-1H-benzimidazol-5-il)-1,3-oksazol-5-il)-2-metilfenil)karbamoil)-1-pirolidinil)-2-okso-1-feniletil)karbamat; metil (R)-2-((S)-2-(S-(2-(2-((S)-1-((R)-2-(dimetilamino)-2-fenilacetil)pirolidin-2-il)-1H-benzo[d]imidazol-5-il)oksazol-5-il)-2-metilfenilkarbamoil)pirolidin-1-il)-2-okso-1-feniletilkarbamat; metil ((1R)-2-((2S)-2-((3-(2-(2-((2S)-1-((2R)-2-((metoksikarbonil)amino)-2-fenilacetil)-2-pirolidinil)-1H-benzimidazol-5-il)-1,3-oksazol-5-il)fenil)karbamoil)-1-pirolidinil)-2-okso-1-feniletil)karbamat; 2-((2S)-1-((2R)-2-fenil-2-(1-piperidinil)acetil)-2-pirolidinil)-5-(4-((2-((2S)-1-((2R)-2-fenil-2-(1-piperidinil)acetil)-2-pirolidinil)-1H-imidazol-4-il)etinil)fenil)-1H-benzimidazole; metil ((1S)-1-(((1R,3S,5R)-3-(7-(2-(2-((1R,3S,5R)-2-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-azabiciklo[3.1.0]heks-3-il)-1H-benzimidazol-5-il)etil)-1H-nafto[1,2-d]imidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)karbonil)-2-metilpropil)karbamat; metil ((1S)-2-((1R,3S,5R)-3-(7-(2-(2-((1R,3S,5R)-2-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-azabiciklo[3.1.0]heks-3-il)-1H-benzimidazol-5-il)etil)-1H-nafto[1,2-d]imidazol-2-il)-2-azabiciklo[3.1.0]heks-2-il)-2-okso-1-(tetrahidro-2H-piran-4-il)etil)karbamat; metil ((1S)-1-(((2S)-2-(4-(2-(4-(2-((2S)-1-((2S)-2-((metoksikarbonil)amino)-3-metilbutanoil)-2-pirolidinil)-1H-benzimidazol-5-il)fenil)etil)-1H-imidazol-2-il)-1-pirolidinil)karbonil)-2-metilpropil)karbamat; 1-(ciklopropilacetil)-N-(3-(5-(2-((2S)-1-(ciklopropilacetil)-2-pirolidinil)-1H-benzimidazol-5-il)-1,3-oksazol-2-il)fenil)-L-prolinamide; i 1-(ciklopropilacetil)-N-(3-(2-(2-((2S)-1-(ciklopropilacetil)-2-pirolidinil)-1H-benzimidazol-5-il)-1,3-oksazol-5-il)fenil)-L-prolinamid; ili njegova farmaceutski prihvatljiva sol.
16. Smjesa koja sadrži spoj prema bilo kojem od zahtjeva 1 do 15, ili njegova farmaceutski prihvatljiva sol, i farmaceutski prihvatljiv nosač.
17. Smjesa prema zahtjevu 16 koja dalje sadrži jedan ili dva dodatna spoja s anti-HCV aktivnošću.
18. Smjesa prema zahtjevu 17 gdje je barem jedan od dodatnih spojeva interferon ili ribavirin.
19. Smjesa prema zahtjevu 18 gdje se interferon izabire između interferona alfa 2B, pegiliranog interferona alfa, konsenzus interferona, interferona alfa 2A, i limfoblastoidnog interferona tau.
20. Smjesa prema zahtjevu 17 gdje se barem jedan od dodatnih spojeva izabire između interleukina 2, interleukina 6, interleukina 12, spoja koji potiče razvoj odgovora pomoćnih T stanica tipa 1, interferirajuće RNA, anti-sense RNA, imikvimoda, ribavirina, inhibitora dehidrogenaze inozin 5’-monofosfata, amantadina, i rimantadina.
21. Smjesa prema zahtjevu 17 gdje je barem jedan od dodatnih spojeva učinkovit u inhibiciji funkcije cilja izabranog između HCV metaloproteaze, HCV serin proteaze, HCV polimeraze, HCV helikaze, HCV NS4B proteina, HCV ulaza, HCV sastavljanja, HCV izlaza, HCV NS5A proteina, i IMPDH za liječenje HCV infekcije.
22. Spoj prema bilo kojem od zahtjeva 1 do 15 ili njegova farmaceutski prihvatljiva sol za uporabu u postupku liječenja HCV infekcije.
23. Spoj za uporabu prema zahtjevu 22 koja dalje obuhvaća primjenu jednog ili dva dodatna spoja s anti-HCV aktivnošću prije, nakon ili istodobno sa spojem iz zahtjeva 1, ili njegova farmaceutski prihvatljiva sol.
24. Spoj za uporabu prema zahtjevu 23 gdje je barem jedan od dodatnih spojeva interferon ili ribavirin.
25. Spoj za uporabu prema zahtjevu 24 gdje se interferon izabire između interferona alfa 2B, pegiliranog interferona alfa, konsenzus interferoan, interferona alfa 2A, i limfoblastoidnog interferona tau.
26. Spoj za uporabu prema zahtjevu 23 gdje se barem jedan od dodatnih spojeva izabire između interleukina 2, interleukina 6, interleukina 12, spoja koji potiče razvoj odgovora pomoćnih T stanica tipa 1, interferirajuće RNA, anti-sense RNA, imikvimoda, ribavirina, inhibitora dehidrogenaze inozin 5’-monofosfata, amantadina, i rimantadina.
27. Spoj za uporabu prema zahtjevu 23 gdje je barem jedan od dodatnih spojeva učinkovit u inhibiciji funkcije cilja izabranog između HCV metaloproteaze, HCV serin proteaze, HCV polimeraze, HCV helikaze, HCV NS4B proteina, HCV ulaza, HCV sastavljanja, HCV izlaza, HCV NS5A proteina, i IMPDH za liječenje HCV infekcije.
HRP20130063AT 2009-02-17 2013-01-24 Inhibitori virusa hepatitisa c HRP20130063T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15318609P 2009-02-17 2009-02-17
US12/701,919 US8809548B2 (en) 2009-02-17 2010-02-08 Hepatitis C virus inhibitors
PCT/US2010/023582 WO2010096302A1 (en) 2009-02-17 2010-02-09 Hepatitis c virus inhibitors

Publications (1)

Publication Number Publication Date
HRP20130063T1 true HRP20130063T1 (hr) 2013-02-28

Family

ID=42631140

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130063AT HRP20130063T1 (hr) 2009-02-17 2013-01-24 Inhibitori virusa hepatitisa c

Country Status (28)

Country Link
US (2) US8809548B2 (hr)
EP (1) EP2398794B1 (hr)
JP (1) JP5612612B2 (hr)
KR (1) KR20110124774A (hr)
CN (1) CN102395579B (hr)
AR (1) AR075510A1 (hr)
AU (2) AU2010216227A1 (hr)
BR (1) BRPI1008846A2 (hr)
CA (1) CA2752579A1 (hr)
CL (1) CL2011002016A1 (hr)
CO (1) CO6400192A2 (hr)
DK (1) DK2398794T3 (hr)
EA (1) EA019976B1 (hr)
ES (1) ES2400951T3 (hr)
HK (1) HK1163067A1 (hr)
HR (1) HRP20130063T1 (hr)
IL (1) IL214098A (hr)
MX (1) MX2011008045A (hr)
NZ (1) NZ594068A (hr)
PE (1) PE20120258A1 (hr)
PL (1) PL2398794T3 (hr)
PT (1) PT2398794E (hr)
SG (1) SG173440A1 (hr)
SI (1) SI2398794T1 (hr)
SM (1) SMT201300043B (hr)
TW (1) TWI438200B (hr)
WO (1) WO2010096302A1 (hr)
ZA (1) ZA201105722B (hr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201071034A1 (ru) * 2008-04-15 2011-06-30 Интермьюн, Инк. Новые макроциклические ингибиторы репликаций вируса гепатита с
SG172352A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
JP2012513410A (ja) 2008-12-23 2012-06-14 アボット・ラボラトリーズ 抗ウイルス化合物
US8394968B2 (en) * 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI438200B (zh) * 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
AU2013204195B2 (en) * 2009-02-27 2016-09-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
SG174146A1 (en) * 2009-02-27 2011-10-28 Enanta Pharm Inc Hepatitis c virus inhibitors
US8507522B2 (en) * 2009-03-06 2013-08-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2541571C2 (ru) * 2009-04-15 2015-02-20 Эббви Инк. Противовирусные соединения
EA027493B1 (ru) 2009-05-13 2017-07-31 Джилид Фармассет Ллс Промежуточные соединения для получения противовирусного соединения
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
NZ591973A (en) * 2009-06-11 2013-03-28 Abbott Lab Anti-viral compounds to treat hcv infection
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
AU2010274001A1 (en) 2009-07-16 2012-02-23 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of Flavivirus infections
KR20120076343A (ko) * 2009-09-04 2012-07-09 글락소스미스클라인 엘엘씨 화합물
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8927709B2 (en) 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110137633A1 (en) * 2009-12-03 2011-06-09 Abbott Laboratories Anti-viral compounds and methods of identifying the same
WO2011081918A1 (en) 2009-12-14 2011-07-07 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20110152246A1 (en) * 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
WO2011075615A1 (en) * 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
WO2011087740A1 (en) 2009-12-22 2011-07-21 Schering Corporation Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2013518060A (ja) 2010-01-25 2013-05-20 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルス阻害剤
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
EP2542074A4 (en) * 2010-03-04 2014-05-14 Enanta Pharm Inc PHARMACEUTICAL COMBINATION ACTIVE AGENTS AS HCV REPLICATION INHIBITORS
AU2011232331A1 (en) 2010-03-24 2012-10-11 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of Flavivirus infections
WO2011127350A1 (en) 2010-04-09 2011-10-13 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US20130296311A1 (en) * 2010-05-28 2013-11-07 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US8778938B2 (en) 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
ES2700542T3 (es) 2010-06-24 2019-02-18 Gilead Sciences Inc Composición farmacéutica que comprende un derivado de pirazolo[1,5-A]pirimidina como un agente antiviral
MX2012014918A (es) 2010-06-28 2013-04-08 Vertex Pharma Compuestos y metodos para tratamiento o prevencion de infecciones por flavivirus.
EP2585448A1 (en) 2010-06-28 2013-05-01 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
SG187183A1 (en) * 2010-08-04 2013-02-28 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US8697704B2 (en) 2010-08-12 2014-04-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
AU2011292040A1 (en) 2010-08-17 2013-03-07 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of Flaviviridae viral infections
US8859595B2 (en) 2010-08-26 2014-10-14 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis C virus
MX2013004655A (es) 2010-10-26 2013-08-27 Presidio Pharmaceuticals Inc Inhibidores del virus de la hepatitis c.
RU2452735C1 (ru) 2010-11-30 2012-06-10 Александр Васильевич Иващенко Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
MX2013006828A (es) * 2010-12-16 2014-10-14 Abbvie Inc Compuestos antivirales.
CN103649079B (zh) 2010-12-22 2016-11-16 Abbvie公司 丙型肝炎抑制剂及其用途
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) * 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP5669984B2 (ja) 2011-05-18 2015-02-18 エナンタ ファーマシューティカルズ インコーポレイテッド ５−アザスピロ［２．４］ヘプタン−６−カルボン酸およびその誘導体の製造方法
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
WO2013016492A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Thiophene compounds
WO2013021337A1 (en) * 2011-08-08 2013-02-14 Lupin Limited Antiviral compounds with a fused tricyclic ring
WO2013021344A1 (en) 2011-08-08 2013-02-14 Lupin Limited Imidazole derivatives as antiviral agents
NZ623396A (en) 2011-09-16 2016-07-29 Gilead Pharmasset Llc Methods for treating hcv
KR20140079830A (ko) * 2011-10-18 2014-06-27 이난타 파마슈티칼스, 인코포레이티드 신규한 벤즈이미다졸 유도체의 제조 방법
PT2794611T (pt) 2011-12-22 2017-12-06 Gilead Sciences Inc Pirazolo[1,5-a]pirimidinas como agentes antivirais
CA2858659A1 (en) 2011-12-28 2013-07-04 Janssen R&D Ireland Hetero-bicyclic derivatives as hcv inhibitors
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG11201404475TA (en) 2012-02-10 2014-08-28 Lupin Ltd Antiviral compounds with a dibenzooxaheterocycle moiety
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
IN2014DN09173A (hr) 2012-04-17 2015-07-10 Gilead Sciences Inc
LT2950786T (lt) 2013-01-31 2020-03-10 Gilead Pharmasset Llc Dviejų antivirusinių junginių preparatų kompozicija
RU2507201C1 (ru) 2013-02-07 2014-02-20 Александр Васильевич Иващенко Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
TW201526899A (zh) 2013-02-28 2015-07-16 Alios Biopharma Inc 醫藥組成物
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP3021845A1 (en) 2013-07-17 2016-05-25 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2153987A1 (en) 1993-01-14 1994-07-21 U. Prasad Kari Amino acids and peptides having modified terminals
US5654451B1 (en) * 1993-01-14 2000-02-22 Magainin Pharma Amino acids and peptides having modified c-terminals and modified n-terminals
US5830905A (en) * 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
AU2003249977A1 (en) 2002-07-05 2004-01-23 Axxima Pharmaceuticals Ag Imidazole compounds for the treatment of hepatitis c virus infections
US20050069522A1 (en) 2002-08-12 2005-03-31 Richard Colonno Combination pharmaceutical agents as inhibitors of HCV replication
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN1902198A (zh) * 2003-12-22 2007-01-24 鲁汶天主教大学研究开发部 咪唑并[4,5－c]吡啶化合物和抗病毒治疗的方法
WO2007084413A2 (en) * 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
KR20070083484A (ko) * 2004-07-14 2007-08-24 피티씨 테라퓨틱스, 인크. Ｃ형 간염 치료 방법
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
GB2438802A (en) 2005-02-28 2007-12-05 Univ Rockefeller Structure of the hepatitis C virus NS5A protein
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
MX2007015783A (es) * 2005-06-22 2008-02-21 Takeda Pharmaceutical Tableta que contiene un ingrediente dificilmente soluble.
BRPI0615934A2 (pt) 2005-09-16 2011-05-31 Arrow Therapeutics Ltd composto ou um sal farmaceuticamente aceitável do mesmo, uso de um derivado de bifenila, composição farmacêutica, e, produto
WO2007058384A1 (en) 2005-11-17 2007-05-24 Osaka University Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
US7915411B2 (en) 2005-12-21 2011-03-29 Abbott Laboratories Anti-viral compounds
ES2378473T3 (es) 2005-12-21 2012-04-12 Abbott Laboratories Compuestos antivirales
SG133452A1 (en) 2005-12-30 2007-07-30 Novartis Ag Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
JP2009523732A (ja) * 2006-01-13 2009-06-25 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎の治療方法
GB0608899D0 (en) * 2006-05-05 2006-06-14 Leuven K U Res & Dev Novel viral replication inhibitors
MX2008014990A (es) 2006-05-30 2008-12-09 Arrow Therapeutics Ltd Derivados de bifenilo y su uso en el tratamiento de hepatitis c.
JP2010504281A (ja) 2006-07-27 2010-02-12 エミスフェアー・テクノロジーズ・インク アリールスルファニル化合物、および活性薬剤を送達するための組成物
US20100158862A1 (en) * 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2097405A2 (en) 2006-11-21 2009-09-09 Smithkline Beecham Corporation Anti-viral compounds
WO2008133753A2 (en) 2006-12-20 2008-11-06 Abbott Laboratories Anti-viral compounds
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
PL2250163T3 (pl) 2008-02-12 2012-10-31 Bristol Myers Squibb Co Inhibitory wirusa zapalenia wątroby typu C
BRPI0907733A2 (pt) 2008-02-12 2015-07-14 Bristol Myers Squibb Co Inibidores do vírus da hepatite c
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2391600T3 (es) 2008-02-13 2012-11-28 Bristol-Myers Squibb Company Imidazoli bifenil imidazoles como inhibidores del virus de la hepatitis C
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8383094B2 (en) 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010062821A1 (en) 2008-11-28 2010-06-03 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
BRPI0922366B8 (pt) 2008-12-03 2021-05-25 Presidio Pharmaceuticals Inc composto, composição farmacêutica e uso de um composto
CN102300462B (zh) 2008-12-03 2015-01-28 普雷西迪奥制药公司 Hcv ns5a的抑制剂
TWI438200B (zh) * 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8394968B2 (en) * 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG174146A1 (en) * 2009-02-27 2011-10-28 Enanta Pharm Inc Hepatitis c virus inhibitors
US8673954B2 (en) * 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8101643B2 (en) * 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
TWI476190B (zh) * 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
TW201038559A (en) * 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
EA027493B1 (ru) * 2009-05-13 2017-07-31 Джилид Фармассет Ллс Промежуточные соединения для получения противовирусного соединения
JP2012528195A (ja) * 2009-05-29 2012-11-12 メルク・シャープ・アンド・ドーム・コーポレーション Ｃ型肝炎などの疾患を処置するための３つの結合アリール部分で構成された抗菌性化合物
WO2010148006A1 (en) * 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8927709B2 (en) * 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011031934A1 (en) * 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors

Also Published As

Publication number Publication date
IL214098A (en) 2015-05-31
CO6400192A2 (es) 2012-03-15
SG173440A1 (en) 2011-09-29
NZ594068A (en) 2013-04-26
CN102395579A (zh) 2012-03-28
KR20110124774A (ko) 2011-11-17
TWI438200B (zh) 2014-05-21
US20100215616A1 (en) 2010-08-26
SI2398794T1 (sl) 2013-05-31
SMT201300043B (it) 2013-07-09
IL214098A0 (en) 2011-08-31
JP5612612B2 (ja) 2014-10-22
PL2398794T3 (pl) 2013-06-28
EP2398794A1 (en) 2011-12-28
MX2011008045A (es) 2011-08-17
CL2011002016A1 (es) 2012-01-20
AU2010216227A1 (en) 2011-08-04
EA019976B1 (ru) 2014-07-30
PT2398794E (pt) 2013-03-14
US8809548B2 (en) 2014-08-19
DK2398794T3 (da) 2013-04-29
ES2400951T3 (es) 2013-04-15
ZA201105722B (en) 2013-01-30
JP2012518000A (ja) 2012-08-09
EP2398794B1 (en) 2013-01-16
TW201040160A (en) 2010-11-16
AR075510A1 (es) 2011-04-06
AU2015275241A1 (en) 2016-02-04
HK1163067A1 (en) 2012-09-07
CN102395579B (zh) 2014-03-12
WO2010096302A1 (en) 2010-08-26
EA201101082A1 (ru) 2012-02-28
US20140205564A1 (en) 2014-07-24
PE20120258A1 (es) 2012-03-29
BRPI1008846A2 (pt) 2019-09-24
CA2752579A1 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
HRP20130063T1 (hr) Inhibitori virusa hepatitisa c
JP2012518000A5 (hr)
HRP20160410T1 (hr) Inhibitori hepatitis c virusa
JP2011530531A5 (hr)
HRP20120706T1 (hr) Imidazolil bifenil imidazoli kao inhibitori virusa hepatitisa c
HRP20120440T1 (hr) Inhibitori virusa hepatitisa c
JP2010500414A5 (hr)
JP2013532725A5 (hr)
JP2014513690A5 (hr)
JP2013510853A5 (hr)
JP2010500415A5 (hr)
JP2012523415A5 (hr)
JP2013510857A5 (hr)
DOP2011000298A (es) Metilo[(2s)-1-{(2s)-2-[5-(10-{2-[(2s)-1-{(2s)-2-[(metoxicarbonil) amino]-3- metilbutanoilo} pirrolidina-2-yl]-1h-imidazol-5-yl}-6-fenilindol[1,2-c][1,3] benzoxazin-3-yl)-1h-imidazol-2-yl]pirrolidina-1-yl} -3-metilo-1-oxobutan-2-yl]carbamato y uso del mismo para tratar la infección por vhc
JP2012522056A5 (hr)
RS54282B1 (en) SOLID MIXTURES
JP2010500413A5 (hr)
JP2012528161A5 (hr)
JP2012522053A5 (hr)
NZ600505A (en) Hepatitis c virus inhibitors
JP2012528166A5 (hr)
NZ600608A (en) 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
JP2012523457A5 (hr)
JP2011511841A5 (hr)
NZ710567A (en) Antiviral compounds